Pedro Justicia Lirio (MSc)
Graduated in Biotechnology with a Mention in Biosalud from the University of Granada (2014 – 2018). In the 2016/2017 academic year, he made a stay as a collaborating student in the Department of Genetics of the Faculty of Sciences. In the academic year 2017/2018 he carried out the Final Degree Project in the same department, directed by Francisco David Carmona López, conducting a current and extensive review on Synthetic Biology and its application in Regenerative Medicine («Synthetic Biology and Regenerative Medicine» ). In 2018, he received a grant from the Scientific Foundation of the Spanish Association Against Cancer (AECC) to join a cancer research center as an internship student. Directed by Dr. Francisco Martín Molina, he joins the Pfizer-University of Granada-Junta de Andalucía Center for Genomics and Oncology Research (GENYO), to the Cell and Gene Therapy group, for 2 months. In October 2018, he stayed in Dr. Martín’s group to carry out the Master’s Thesis, in a gene therapy project for cancer immunotherapy: “regulation of the expression of Chimeric Antigen Receptors (CARs) for a safer and more efficient CAR-CD19 therapy ”, the achievement of which has brought important data and patent projects to the group. In December 2019, he was hired by LentiStem Biotech after obtaining an Industrial Doctorate (Helps for the Training of Doctors in Companies), where he began with the completion of his doctoral thesis in parallel with the development of the company’s activity, working in the development of 4th generation inducible CARs, as well as in the optimization and improvement of the production of lentiviral vectors.
LinkedIn: Pedro Luis Justicia Lirio